Maxim analyst Jason McCarthy downgraded Akari Therapeutics (AKTX) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics announces strategic partnership with WuXi XDC
- Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright
- Akari Therapeutics trading halted, news pending
- Upcoming Stock Splits This Week (March 30 to April 2) – Stay Invested
- Akari Therapeutics Announces ADS Ratio Change, Reverse Split